<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010192</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01404</org_study_id>
    <secondary_id>0037</secondary_id>
    <secondary_id>CDR0000068454</secondary_id>
    <secondary_id>OSU-0037</secondary_id>
    <secondary_id>NCI-130</secondary_id>
    <secondary_id>OSU-00H0223</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00010192</nct_id>
  </id_info>
  <brief_title>Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>A Phase I Trial Of Rituximab And Interleukin-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or&#xD;
      deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may&#xD;
      stimulate a person's white blood cells to kill cancer cells. Combining rituximab with&#xD;
      interleukin-2 may kill more cancer cells. Phase I trial to study the effectiveness of&#xD;
      rituximab plus interleukin-2 in treating patients who have hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Determine the dose-limiting toxicity of rituximab followed by low-dose and&#xD;
      intermediate-dose pulse interleukin-2 (IL-2) in patients with CD20-positive B-cell lymphoid&#xD;
      malignancy.&#xD;
&#xD;
      Determine the maximum tolerated dose of intermediate-dose pulse IL-2 in this patient&#xD;
      population.&#xD;
&#xD;
      Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of intermediate-dose pulse aldesleukin.&#xD;
&#xD;
      Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose&#xD;
      aldesleukin subcutaneously (SC) on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose&#xD;
      aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84. Cohorts of 3-6 patients receive&#xD;
      escalating doses of intermediate-dose pulse aldesleukin until the maximum tolerated dose&#xD;
      (MTD) is reached. The MTD is defined as the dose preceding that at which at least 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the dose preceding that at which at least 2 of 6 patients experience DLT using NCI CTC version 2.0</measure>
    <time_frame>2 weeks</time_frame>
    <description>Data collected will be descriptive and provide limited estimates of variability given the small sample sizes at each dose level.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>B-cell Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Noncontiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage III Adult Burkitt Lymphoma</condition>
  <condition>Stage III Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage III Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage III Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage III Grade 1 Follicular Lymphoma</condition>
  <condition>Stage III Grade 2 Follicular Lymphoma</condition>
  <condition>Stage III Grade 3 Follicular Lymphoma</condition>
  <condition>Stage III Mantle Cell Lymphoma</condition>
  <condition>Stage III Marginal Zone Lymphoma</condition>
  <condition>Stage III Small Lymphocytic Lymphoma</condition>
  <condition>Stage IV Adult Burkitt Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage IV Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage IV Grade 1 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 2 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 3 Follicular Lymphoma</condition>
  <condition>Stage IV Mantle Cell Lymphoma</condition>
  <condition>Stage IV Marginal Zone Lymphoma</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (rituximab and aldesleukin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose aldesleukin SC on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rituximab and aldesleukin)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (rituximab and aldesleukin)</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (rituximab and aldesleukin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (rituximab and aldesleukin)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or immunophenotypically proven CD20-positive B-cell lymphoproliferative&#xD;
             disorder&#xD;
&#xD;
               -  Recurrent or progressive low-grade B-cell lymphoma with at least one prior&#xD;
                  chemotherapy regimen (may have included monoclonal antibody)&#xD;
&#xD;
               -  Relapsed intermediate-grade or high-grade B-cell lymphoma or B-lineage acute&#xD;
                  lymphoblastic leukemia and patient not a candidate for, refused, or failed prior&#xD;
                  hematopoietic stem cell transplantation&#xD;
&#xD;
          -  No chronic lymphocytic leukemia or lymphoma with more than 5,000/mm3circulating&#xD;
             lymphoma cells&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Must have failed standard curative therapy&#xD;
&#xD;
          -  No CNS or leptomeningeal metastasis&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL (transfusion allowed)&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
          -  AST no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
          -  No prior unstable coronary artery disease&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  DLCO and FEV1 at least 50% of predicted&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
          -  No infection requiring IV antibiotic therapy within the past 4 weeks&#xD;
&#xD;
          -  No other major illness that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior antibody therapy allowed&#xD;
&#xD;
          -  Prior interleukin-2 or interferon alfa allowed&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior systemic corticosteroids&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierluigi Porcu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

